Week four, celebrating gains, measuring progress beyond the mirror, and planning month two At the end of the first 30 days we review your experience and your data
In addition, one must gain FDA approval by clinically demonstrating that the delivery of the microbe-encapsulated GLP-1 through this oral route leaves the drug molecule itself unchanged (with no post-translational modifications), that it has a similar pharmacokinetic profile to the reference molecule, and that it shows no adverse effects
Because the drugs treat and help manage obesity, insulin resistance, inflammation, and your metabolism, they can also affect skin diseases connected to those conditions
Bloating and abdominal discomfort are common during the first few weeks and typically improve as the body adjusts to delayed gastric emptying
Elevated GH levels subsequently trigger the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic effects, including protein synthesis, lipolysis (fat breakdown), and tissue repair
Consider tirzepatide (Zepbound/Mounjaro) if: You want a proven, FDA-approved medication available today You prefer a drug with years of real-world safety data You have insurance coverage for weight management medications You have type 2 diabetes (Mounjaro is indicated for T2D) You are sensitive to GI side effects (lower nausea rate: 31% vs 43%) You want the option of pre-filled pens for easier injection Consider waiting for retatrutide if: You have plateaued on tirzepatide or semaglutide and want the next-generation option You have MASLD or fatty liver disease (glucagon component reduces liver fat by 82%) Maximum possible weight loss is your primary goal You are eligible for and enrolled in a clinical trial You are comfortable waiting until 2027-2028 for availability On switching from tirzepatide to retatrutide: Once retatrutide is approved, switching will likely be straightforward since both are Lilly products
